A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy

CONCLUSIONS: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.PMID:37668202 | DOI:10.4111/icu.20230128

Source: Clinical Prostate Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Seung-Hwan Jeong Sang Eun Yeon Su Youn Kim Tae Gyun Kwon Seong Soo Jeon Young Deuk Choi Dongdeuk Kwon Byung Ha Chung Sung-Hoo Hong Byung Hoon Kim Hyo Jin Lee Sang Joon Shin Woo Suk Choi Sung Woo Park Taek Won Kang Seok Joong Yun Jin Seon Cho See Min Choi Source Type: research